President Donald Trump’s long-awaited threat to impose pharmaceutical tariffs may not pose as much of a challenge as drugmakers once feared, following his new drug-pricing deal with Pfizer, News.Az reports citing CNBC. That deal brought relief and clarity to Pfizer and the broader pharmaceutical industry, signaling that many drugmakers could strike similar deals that would make them immune to the levies for most of Trump’s term. The Pfizer deal adds certainty for drugmakers and shifts the president’s policies “potentially away from Pharma tariffs,” BMO Capital Markets analyst Evan Seigerman said in a note on Tuesday. He said that’s in part because Medicaid pricing is already similar to international levels for most drugs. Gileadis among the drugmakers with greater exposure to Medicaid, with the program making up around 20% of its domestic sales.